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Case Reports
Percutaneous Closure of an Iatrogenic
Atrial Septal Defect
James P. Sur,1 MD, Francis D. Pagani,2 MD, PhD, and Mauro Moscucci,1* MD
The use of the Tandem HeartTM percutaneous ventricular assist device (Tandem Heart
pVAD, Cardiac Assist technologies, Pittsburgh, PA) as a bridge to recovery or to other
cardiopulmonary support systems has been rising. One requirement for placement of
this device is an intraatrial septostomy which is usually closed during the surgical
insertion of more permanent ventricular assist devices. We present a case of a 62-
year-old man with a residual acquired atrial septal defect (ASD) from Tandem HeartTM
placement, which could not be closed surgically during insertion of left and right ven-
tricular assist devices. The patient remained intubated and hypoxemic after removal of
his right ventricular assist device due to the presence of persistent right to left shunt-
ing. With closure of the ASD using an 8-mm Amplatzer1 septal occluder (ASO; AGA
Medical Corp., Golden Valley, MN) the patient stabilized and was successfully extu-
bated. ' 2009 Wiley-Liss, Inc.
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INTRODUCTION
Treatment options for patients with cardiogenic
shock and systolic heart failure have been expanding
with the use of extracorporeal life support such as the
Tandem HeartTM percutaneous left ventricular assist
device (pVAD). These systems can be used as a bridge
to recovery or as a bridge to more permanent surgi-
cally implanted ventricular assist devices (VAD). First
described in 2001 by Thiele et al., the Tandem
HeartTM pVAD is a low-speed centrifugal continuous
flow pump that can be used as an effective bridge for
short-term circulatory support [1].
The insertion of the Tandem HeartTM pVAD
requires an atrial septostomy in order to allow place-
ment of the left atrial cannula. We describe a case
where a patient who required a Tandem HeartTM de-
vice as a bridge to right and left ventricular assist de-
vice (RVAD/LVAD) support had a residual acquired
atrial septal defect (ASD) upon removal of the Tandem
HeartTM device. Routine surgical closure of the intraa-
trial septostomy could not be performed in this case
due to technical difficulty. The degree of shunting
anticipated through the small acquired ASD was felt to
be minimal, given the TEE results, and the intraopera-
tive decision was made to leave the ASD and to con-
sider closing using a percutaneous method if clinically
significant. Significant right to left shunting through
the residual acquired ASD causing refractory hypoxe-
mia was unmasked following RVAD removal during
weaning of mechanical ventilatory support. Successful
percutaneous closure of the ASD was then performed
using an Amplatzer1 septal occluder (ASO) device
with rapid correction of the patient’s hypoxemia and
ventilatory support needs.
CASE REPORT
A 62-year-old man with a history of severe ischemic
dilated cardiomyopathy was admitted to our hospital
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with multisystem organ failure and New York Heart
Association functional class IV decompensated conges-
tive heart failure. Physical examination revealed mild
distress, a blood pressure of 74/49, biventricularly
paced at a HR of 89 beats per minute, breathing 22
times a minute saturating 96% on room air. His car-
diac examination was significant for a holosystolic
murmur over the mitral window radiating to the axilla
as well as an S3. His extremities were cool with sig-
nificant pitting edema to the waist. His chest X-ray
revealed severe cardiomegaly, mild pulmonary edema,
and pleural effusions. Transthoracic echocardiogram
confirmed biventricular dilatation and dysfunction with
severe mitral regurgitation and moderate tricuspid re-
gurgitation. His admission labs were significant for
blood urea nitrogen (BUN) of 76 mg/dL, serum creati-
nine (SCr) of 1.9 mg/dL, and glomerular filtration
(GFR) rate of 38 mL/min worsened from his baseline
BUN of 42 mg/dL, SCr of 1.1 mg/dL, and GFR of 60
mL/min. His coagulation studies revealed a prothrom-
bin time of 37.9 sec and an international normalized
ratio (INR) of 4.1 while on Coumadin therapy.
The patient was admitted to the coronary care unit
where IV diuretics and multiple IV inotropic agents
were trialed with no significant success. Eventually,
the patient’s status gradually deteriorated to cardio-
genic shock and worsening organ function evidenced
by a rise in his BUN to 99 mg/dL, SCr to 2.9 mg/dL,
and persistent elevation of his INR at 1.8 off all anti-
coagulation. On day 18 of his admission, while trans-
plant workup was being performed, he was taken to
the cardiac catheterization lab for hemodynamic
assessment and possible placement of intraaortic bal-
loon pump (IABP) and/or Tandem HeartTM device. An
IABP was placed and with that his hemodynamics
were as follows: a right atrial pressure of 28 mmHg,
pulmonary artery pressure of 59/30 mm Hg (44), pul-
monary capillary wedge pressure of 24 mm Hg, and a
systemic arterial pressure of 77/50 mm Hg (57). Ther-
modilution cardiac output and cardiac index were 3.9
L/min and 1.89 L/min/m2, respectively. Fick cardiac
output and cardiac index were 4.04 L/min and 1.95 L/
min/m2, respectively. Pulmonary artery blood satura-
tion was 43.1%, while femoral arterial blood saturation
was 92%. The calculated systemic vascular resistance
at the time, with the balloon pump in place, was
574.26 dyne sec cm25. The decision at that time was
made to insert a Tandem HeartTM pVAD for better he-
modynamic support. Given the concern for a new
onset of fevers with possible infection and his multi-
system organ dysfunction, surgical VAD placement
was deferred.
The Tandem HeartTM was inserted in the cardiac
catheterization lab via the right femoral vein and femo-
ral artery in the standard approach [1]. A transseptal
puncture was performed using a BRK Brockenbrough
needle, and a Mullins sheath was then inserted into the
left atrium. An Inoue guidewire (Toray International,
Houston, TX) was advanced into the left atrium
through the Mullins sheath and the sheath was then
removed. Over an Inoue guidewire, a 21 French (Fr)
left atrial catheter, after using a dilator, was positioned
in the LA across the intraatrial septum. A 15 Fr arte-
rial catheter was positioned in the right common iliac
artery via a right femoral arteriotomy. Initial settings
of the Tandem HeartTM device were 4000 RPM with
flow rates of 3 L/min providing the intended partial as-
sistance while preserving aortic valve opening and the
prevention of stagnation of flow in the aortic root. All
cannulae positions were confirmed with fluoroscopy.
With Tandem HeartTM support, the patient had
improvement in his hemodynamics and organ function.
His urinary output increased from less than 2 L/day to
a urinary output of over 5 L/day with net output
improving from a daily net positive balance to a net
negative balance of over 1.5 L a day. His BUN
improved to 79 mg/dL and SCr to 1.7 mg/dL after 3
days of Tandem HeartTM support. He had stable oxy-
genation and was at most supported with 3 L of oxy-
gen by nasal cannulation. After the exclusion of active
infection and stable noncardiac organ function, he was
taken on hospital day 21 for definitive placement of
both right and left ventricular assist devices. Successful
placement of a Heartmate XVE1 LVAD (Thoratec
Corp., Pleasanton, CA) and an Abiomed BVS 50001
RVAD (Abiomed, Danvers, MA) was performed. At
the time of surgery, due to severe continuous calcifica-
tion of the diaphragm that extended onto the inferior
vena cava (IVC) and inferior and lateral aspect of the
right atrium, a caval snare could not be placed to
selectively drain the IVC. The right atrium ultimately
was never opened and therefore the iatrogenic ASD
was not directly visualized. Intraoperative TEE, how-
ever, revealed no significant shunting across the ASD
when both the RVAD and LVAD systems were func-
tioning. Biventricular support was maintained for 17
days with resolution of his organ dysfunction demon-
strated by a drop in his BUN to 40 mg/dL and SCr to
0.9 mg/dL. At this point, he continued to have a low
oxygen requirement of 1–2 L by nasal cannula, with
pulse oximeter saturations of 95–99%. In view of sig-
nificant improvement of right ventricular function he
returned to the operating room on hospital day 38,
postoperative day 17, for RVAD removal. Following
the removal of the RVAD, the patient developed sig-
nificant difficulty with oxygenation during weaning of
mechanical ventilatory support and nitric oxide and he
was unable to be extubated following the procedure.
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He required assisted ventilation with fractions of
inspired oxygen (FiO2) of 100% with adjunctive
inhaled nitric oxide at 20 ppm to maintain oxygen sat-
urations in the 90% and higher range by arterial blood
gas measurement. His LVAD flows were maintained at
a level of 5–6 L/min. With only trivial increase in his
central venous pressure, concern for RV failure after
RVAD removal was not a likely explanation for his re-
Fig. 1. A: ASD with color flow Doppler demonstrating right to left shunting. B: Following
deployment of the Amplatzer septal occluder device, no residual shunt is seen by TEE. [Color
figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]
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fractory hypoxemia. Additionally, his organ function
was maintained following RVAD removal. Transtho-
racic echo performed at bedside with an agitated saline
bubble study revealed marked right to left shunting.
Therefore, it was decided to proceed with percutaneous
closure of the ASD.
The patient was brought to the cath lab 4 days after
RVAD removal on hospital day 42, postoperative day
21 for percutaneous closure of the ASD. With trans-
esophageal echocardiography (TEE) and fluoroscopic
guidance using a sizing balloon, the ASD was sized at
7 mm in diameter. Initial TEE demonstrated exclusive
right to left shunting through the ASD (Fig. 1A). Biva-
lirudin (AngiomaxTM The Medicines Company, Parsip-
pany, NJ) was used for anticoagulation due to a mildly
positive HIT ELISA assay. Using standard techniques,
an 8-mm ASO device was successfully deployed
across the ASD [2,3]. Once deployed, correct position-
ing of the 8-mm ASO was confirmed on cinefluoros-
copy and on TEE. Following deployment of the ASO
device, there was no continued shunting seen across
the intraatrial septum (Fig. 1B).
After returning to the ICU, the patient had nearly
immediate improvement in his arterial saturations
(Table I). He was able to be weaned off inhaled nitric
oxide within 24 hr. His FiO2 requirements also dra-
matically improved shortly after he returned from the
procedure. Within 48 hr, on hospital day 44, postoper-
ative day 23 the patient was successfully extubated
and successfully weaned off much of his inotropic sup-
port. His hemodynamic improvement continued and he
was eventually discharged to home after rehabilitation
to await cardiac transplantation.
DISCUSSION
Several authors have reported the discovery of
intraatrial communications with significant right to left
shunting when patients with congestive heart failure
with severely elevated left atrial pressure undergo ab-
rupt reduction in pressure following cannulation with a
LVAD. Infrequent case reports have described the suc-
cessful closure of those defects discovered after LVAD
placement with atrial septal occluder devices [4–6].
Others have identified clinically significant iatrogenic
ASDs after percutaneous transseptal balloon mitral val-
vuloplasty, which were closed using a septal occluder
device as well [7–10]. One group has also reported the
identification and successful percutaneous Amplatzer1
closure of a previously undiscovered patent foramen
ovale (PFO) in two patients while being supported by
a Tandem HeartTM pVAD device [11]. We describe a
case where an acquired persistent ASD that occurred
during the transseptal placement of a Tandem HeartTM
device required closure with a percutaneous approach,
because it could not be closed surgically. Furthermore,
it was only after the removal of RVAD support that
the clinical significance of this residual ASD was
unmasked.
RVAD and LVAD support provide a unique hemo-
dynamic situation in patients with biventricular failure
and an ASD as they reduce both right and left atrial
and ventricular diastolic filling pressures. Given simul-
taneous biventricular unloading when used concomi-
tantly, any shunting that might occur could go under-
appreciated. Usually, the intraatrial septostomy caused
by the Tandem HeartTM device, if not closed surgically
at the time of more invasive support implantation, has
been shown in animals to heal completely at the end
of a 4-to 6-week period [12,13]. If persistent, it usually
results in insignificant shunting in those eventually
weaned off the Tandem HeartTM with no eventual
LVAD placement. In our patient, who had inadequate
time for the septostomy to close on its own, a clini-
cally relevant ASD with significant right to left shunt-
ing was identified at the time of RVAD removal.
The use of anticoagulation during the placement of
such occlusion devices is imperative as thrombosis and
ultimate embolization of thrombus is a risk factor of
this procedure [3]. Great care is taken to exclude
patients who are hypercoagulable when considering the
use of a septal occluder device. Because of reduced
platelets in this patient, evaluation for heparin-induced
thrombocytopenia (HIT) was performed identifying a
mildly positive HIT ELISA assay. Shammas et al.
have previously reported the safe use of bivalirudin in
ASD closure [14]. With this information, we elected to
refrain from using heparin and chose to use bivalirudin
during the placement of the ASO. The patient was also
loaded with clopidogrel (Plavix1, Bristol-Myers
TABLE I. Arterial Blood Gas Measurements Preprocedure (gray) and in the 48 hr Following Closure of the ASD with the
Amplatzer Septal Occluder Device
Date/time pH PaCO2 PaO2 HCO3 %Oxygen saturation %FiO2 PPM of NO
4 hr Preprocedure 7.47 30 73 22 93 65 20
10 hr Post 7.4 35 144 22 97 50 9
24 hr Post 7.47 31 83 22 95 30 –
48 hr Post 7.46 34 83 24 95 6 L NC –
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Squibb, New York, NY) 600 mg in the cath lab and
continued on aspirin 325 mg and clopidogrel 75 mg po
qd for a planned 6 months. To date, he has had no
evidence of thrombotic complication due to the place-
ment or existence of the ASO device.
In conclusion, the acquired ASD from placement of
a Tandem HeartTM pVAD device rarely causes signifi-
cant problems for patients in whom the device is used.
In the situation where patients have a pVAD device
used as a bridge to LVAD support, one needs to con-
sider the possible complications created by the residual
ASD once the Tandem HeartTM device is removed.
This case highlights the possible clinical relevance of
these iatrogenic acquired ASDs and that percutaneous
closure of the residual ASD is an effective treatment
option when surgical closure cannot be performed.
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